Here are the 424B prospectus supplements from Alvotech Warrant (ALVOW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ALVOW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALVOW filings page.
Alvotech is offering 22,666,667 ordinary shares at a public offering price of $3.75 per share pursuant to this prospectus supplement.
The underwriters have a 30-day option to purchase up to 3,400,000 additional ordinary shares. A concurrent private placement of 17,826,666 shares for gross proceeds of approximately $66.85 million was agreed with certain EEA investors and is conditioned on the closing of this offering.
Alvotech is offering ordinary shares pursuant to a preliminary prospectus supplement dated June 15, 2026. The supplement is being filed from an existing shelf registration and describes a primary offering of ordinary shares, with an underwriting option to purchase additional shares.
The supplement discloses a related concurrent private placement to certain European professional clients at the public offering price, conditioned on this offering closing. The company reports 312,153,164 ordinary shares outstanding as of March 31, 2026, recent FDA activity including a Form 483 following a May 2026 inspection of its Reykjavik facility and resubmissions of BLAs for AVT05 and AVT06 on June 4, 2026.